Protecting Motor Neurons from Toxic Insult by Antagonism of Adenosine A2a and Trk Receptors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The death of motor neurons in amyotrophic lateral sclerosis (ALS) is thought to result from the interaction of a variety of factors including excitotoxicity, accumulation of toxic proteins, and abnormal axonal transport. Previously, we found that the susceptibility of motor neurons to excitotoxic insults can be limited by inhibiting signals evoked by brain-derived neurotrophic factor (BDNF) activation of the receptor tyrosine kinase B (TrkB). Here we show that this can be achieved by direct kinase inhibition or by blockade of a transactivation pathway that uses adenosine A2a receptors and src-family kinases (SFKs). Downstream signaling cascades (such as mitogen-activated protein kinase and phosphatidylinositol-3 kinase) are inhibited by these blockers. In addition to protecting motor neurons from excitotoxic insult, these agents also prevent toxicity that follows from the expression of mutant proteins (G85R superoxide dismutase 1; G59S p150 glued) that cause familial motor neuron disease. TrkB, adenosine A2a receptors, and SFKs associate into complexes in lipid raft and nonlipid raft membranes and the signaling from lipids rafts may be particularly important because their disruption by cholesterol depletion blocks the ability of BDNF to render motor neurons vulnerable to insult. The neuroprotective versatility of Trk antagonism suggests that it may have broad utility in the treatment of ALS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Neurotrophins as synaptic modulators
Poo, M.-M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35049004 · Cited by 1,775 · cited 1×
“Thus, although synaptic activity can be enhanced by BDNF-TrkB signaling (Poo, 2001), it is unlikely that BDNF makes motor neurons vulnerable to excitotoxic insult simply by potentiating the capacity of glutamate to excite neurons.”
Backgroundβ-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 1×
“…most effective ways to slow the progression of motor neuron death in model systems of ALS is to modulate excitatory glutamatergic neurotransmission (Rothstein et al., 1993, 2005; Estevez et al., 1995; Kwak and Nakamura, 1995; Carriedo et al., 1996; Roy et al., 1998; Kruman et al., 1999; Van Damme…”
BackgroundCleavage of proBDNF by tPA/Plasmin Is Essential for Long-Term Hippocampal Plasticity
Pang, P. T., Teng, H. K., Zaitsev, E., Woo, N. T., Sakata, K., Zhen, S., Teng, K. K., Yung, W.-H., Hempstead, B. L., & Lu, B. (2004) · Science · doi:10.1126/science.1100135 · Cited by 1,136
Mice lacking brain-derived neurotrophic factor develop with sensory deficits
Ernfors, P., Lee, K.-F., & Jaenisch, R. (1994) · Nature · doi:10.1038/368147a0 · Cited by 1,067 · cited 2×
“Although this is counter-intuitive, because BDNF-TrkB signaling is essen- tial for survival of populations of developing neurons (Jones et al., 1994; Ernfors et al., 1995; Liu et al., 1995; Schwartz et al., 1997; Silos-Santiago et al., 1997), an additional prodeath activity of BDNF has also been…”
BackgroundTsvyetlynska, N. A., Hill, R. H., & Grillner, S. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00201.2005 · Cited by 37
Cited by
Purinergic signalling and disorders of the central nervous system
Burnstock, G. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2605 · Cited by 634
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
McGurk, L., Gomes, E., Guo, L., Mojsilovic-Petrovic, J., Tran, V., Kalb, R. G., Shorter, J., & Bonini, N. M. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.002 · Cited by 409
Self-citationPurinergic signalling: From normal behaviour to pathological brain function
Burnstock, G., Krügel, U., Abbracchio, M. P., & Illes, P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.006 · Cited by 397
Adenosine Receptors and the Central Nervous System
Sebastião, A. M., & Ribeiro, J. A. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-89615-9_16 · Cited by 266
Metadata
- Authors
- Mojsilovic-Petrovic, J., Jeong, G.-B., Crocker, A., Arneja, A., David, S., Russell, D., & Kalb, R. G.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-09-06
- Volume
- 26
- Issue
- 36
- Pages
- 9250-9263
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1991323513
- Cited by
- 143
- References
- 10
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.